Efficacy analysis of three-year subcutaneous SQ-standardized specific immunotherapy in house dust mite-allergic children with asthma

Abstract

The present study aimed to evaluate the efficacy of three-year subcutaneous SQ-standardized specific immunotherapy (SCIT) in house dust mite (HDM)-allergic children with asthma. Ninety children with allergic asthma to HDMs, with or without allergic rhinitis, were randomly divided into two groups, the treatment group and the control group. The treatment group received SCIT combined with standardized glucocorticoid management and the control group received standardized glucocorticoid management alone for a period of three years. The mean daily dose of inhaled corticosteroids (ICSs), a four-week diary recording the symptom scores of asthma, peak expiratory flow (PEF) measurements, skin prick test results and serum immunoglobulin E (IgE) levels were assessed prior to treatment and following one, two and three years of treatment. The median dose of ICS was reduced in the treatment group after two and three years of treatment compared with that of the control group. After three years of treatment, the discontinuation percentage of ICS in the treatment group was higher than that in the control group. The treatment group demonstrated significantly reduced daytime and night-time asthmatic symptom scores, increased PEF values and reduced serum IgE levels after two and three years of treatment compared with those in the control group (P<0.05). In conclusion, three-year SCIT treatment combined with ICS is an effective immunotherapy for children with allergic asthma and resulted in a reduction of the required ICS dose.

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence

“…In a randomized trial that included monosensitized, asthmatic children, SCIT significantly improved asthmatic symptoms and reduced drug intake, associated with a significant decrease in non-specific bronchial hyper-responsiveness [134]. Similar results were observed in other randomized studies, with reduction in fluticasone propionate doses [135], mean medication scores [136], and a higher percentage of patients who discontinued ICS therapy [137,138]. In a prospective study comparing the efficacy of treatment with SCIT or ICS for one year in children with asthma, it was reported that the number of emergency room visits for asthma attacks was significantly lower in the SCIT group than in the ICS group; in addition, pulmonary function was significantly improved in the SCIT group [139].…”

Allergen immunotherapy for allergic asthma: A systematic review and meta‐analysis

“…Fourteen studies reported on this outcome . (Table ) Pooled data from six studies suggested no clear benefit of AIT with an SMD of 0.48 (95% CI −0.21, 1.18; Fig.…”

Anti-allergic effect of Artemisia extract in rats

“…Drug-induced allergic reactions may be serious, as anaphylactic shock may lead to patient fatality (13). Establishing a sensitive and reliable animal model for the study of allergic anaphylaxis is necessary; as a basis for screening and discovering drug allergens in addition to the investigation of drug-induced allergic reaction mechanisms, that are relevant to the prevention and treatment of clinical allergic reactions to drugs (14). However, during the preclinical safety evaluation of drugs, allergic reaction is among the most difficult factors to predict due to the lack of appropriate models for predicting clinical allergic reactions (15).…”